MEI Pharma Appoints Brian T. Powl As Senior Vice President, Marketing


SAN DIEGO, Sept. 15, 2020 /PRNewswire/ -- MEI Pharma, Inc. (NASDAQ: MEIP) ("MEI"), a late-stage pharmaceutical company focused on advancing new therapies for cancer, today announced the appointment of Brian T. Powl as senior vice president, marketing, a new role that will report to David Urso, chief operating officer and general counsel, effective immediately. Mr. Powl joins MEI from Celgene Corporation where he served as vice president, global commercial CART T lead.

"Brian's experience and leadership, coupled with his record of cross-functional team building, are a great fit for MEI as we move forward with our planning for the potential commercial launch of zandelisib and start to actively build out our commercialization capability," said David Urso, chief operating officer and general counsel of MEI Pharma. "Capitalizing on the commercial opportunity of our pipeline as our programs advance in clinical development is a key part of our strategic plan and long-term growth objectives, and Brian's demonstrated success in these areas will be of significant value to MEI."

Mr. Powl holds extensive experience in sales and marketing from leading pharmaceutical and biotech companies, having developed and implemented commercial launches and life cycle strategies for multiple hematologic and solid tumor cancers. Most recently Mr. Powl was vice president, global commercial CAR T lead at Celgene Corporation. Previously, he held other senior level positions at Celgene including leading their flagship multiple myeloma franchise, and earlier held sales and marketing positions at Novartis Oncology, and Centocor, Inc. Mr. Powl holds a BS in Biochemistry from the University of California, San Diego and an MBA in Healthcare Management/Marketing from the Wharton School at the University of Pennsylvania.

Mr. Powl commented, "I'm looking forward to contributing to the MEI team by leveraging all the hard work accomplished to date and building the commercial readiness to achieve the potential that zandelisib represents for patients with hematologic cancers and their physicians at this pivotal point in the company's development."

About MEI Pharma
MEI Pharma, Inc. (Nasdaq: MEIP) is a late-stage pharmaceutical company focused on developing potential new therapies for cancer. MEI Pharma's portfolio of drug candidates contains four clinical-stage assets, including zandelisib, currently in an ongoing Phase 2 clinical trial which may support an accelerated approval marketing application with the U.S. Food and Drug Administration. Each of MEI Pharma's pipeline candidates leverages a different mechanism of action with the objective of developing therapeutic options that are: (1) differentiated, (2) address unmet medical needs and (3) deliver improved benefit to patients either as standalone treatments or in combination with other therapeutic options. For more information, please visit

Forward-Looking Statements 
Under U.S. law, a new drug cannot be marketed until it has been investigated in clinical studies and approved by the FDA as being safe and effective for the intended use. Statements included in this press release that are not historical in nature are "forward-looking statements" within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. You should be aware that our actual results could differ materially from those contained in the forward-looking statements, which are based on management's current expectations and are subject to a number of risks and uncertainties, including, but not limited to, our failure to successfully commercialize our product candidates; costs and delays in the development and or FDA approval, or the failure to obtain such approval, of our product candidates; uncertainties or differences in interpretation in clinical trial results; the impact of the COVID-19 pandemic on our industry and individual companies, including on our counterparties, the supply chain, the execution of our clinical development programs, our access to financing and the allocation of government resources; our inability to maintain or enter into, and the risks resulting from our dependence upon, collaboration or contractual arrangements necessary for the development, manufacture, commercialization, marketing, sales and distribution of any products; competitive factors; our inability to protect our patents or proprietary rights and obtain necessary rights to third party patents and intellectual property to operate our business; our inability to operate our business without infringing the patents and proprietary rights of others; general economic conditions; the failure of any products to gain market acceptance; our inability to obtain any additional required financing; technological changes; government regulation; changes in industry practice; and one-time events. We do not intend to update any of these factors or to publicly announce the results of any revisions to these forward-looking statements.

MEI Pharma Logo. (PRNewsFoto/Marshall Edwards, Inc.)



Cision View original content to download multimedia:

SOURCE MEI Pharma, Inc.


Back to news